Brief: Sight Sciences Announces First Patient Treated In Trident European Trial To Evaluate The Omni® Surgical System In Pseudophakic Eyes With Open-Angle Glaucoma
24/03/2022 20:44
March 24 (Reuters) - Sight Sciences Inc SGHT.O :
* SIGHT SCIENCES ANNOUNCES FIRST PATIENT TREATED IN TRIDENT
EUROPEAN TRIAL TO EVALUATE THE OMNI® SURGICAL SYSTEM IN
PSEUDOPHAKIC EYES WITH OPEN-ANGLE GLAUCOMA
Source text for Eikon: ID:nGNX6LjRXS
Further company coverage: SGHT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sight Sciences
See all newsSight Sciences raises FY 2026 revenue outlook
Brief: Sight Sciences Q1 Revenue USD 19.7 Million Vs. IBES Estimate USD 18.5 Million
Brief: Sight Sciences U.S. District Court Issued Order On Post-Trial Motions In Patent Infringement Case Against Alcon Originally Filed On Sep 16, 2021
Sight Sciences Q4 revenue rises 7%
Brief: Sight Sciences Announces Preliminary, Unaudited Fourth Quarter And Full Year 2025 Financial Highlights